Evidence map›Paper›PMID 35119183›Full record

Trial reportEuropean journal of heart failure2022

Effects of sacubitril/valsartan versus valsartan on renal function in patients with and without diabetes and heart failure with preserved ejection fraction: insights from PARAGON-HF.

Alexander Peikert, Muthiah Vaduganathan, Finnian Mc Causland, Brian L Claggett, Safia Chatur, Milton Packer, Marc A Pfeffer, Faiez Zannad, Martin P Lefkowitz, Burkert Pieske and 3 more

Open access · hybridAbstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in European journal of heart failure, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 1 pooled it
4.8field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 1 synthesis or guideline pooled it, 30 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Observational
  9. Article
  10. Review
  11. Article
  12. Review
  13. Review
  14. Article
  15. Review
  16. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors at 8 institutions in 4 countries.

Alexander PeikertCardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Muthiah VaduganathanCardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Finnian Mc CauslandRenal Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Brian L ClaggettCardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Safia ChaturCardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Milton PackerBaylor Heart and Vascular Hospital, Baylor University Medical Center, Dallas, TX, USA.
Marc A PfefferCardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Faiez ZannadUniversity of Nancy, Nancy, France.
Martin P LefkowitzNovartis, East Hanover, NJ, USA.
Burkert PieskeDepartment of Internal Medicine and Cardiology, Campus Virchow Klinikum, Charité Universitätsmedizin Berlin, Berlin, Germany.
Hans-Dirk DüngenDepartment of Internal Medicine and Cardiology, Campus Virchow Klinikum, Charité Universitätsmedizin Berlin, Berlin, Germany.
John J V McMurrayNew British Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow, UK.
Scott D SolomonCardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Harvard University · USBrigham and Women's Hospital · USBaylor University Medical Center · USCentre Hospitalier Régional et Universitaire de Nancy · FRCharité - Universitätsmedizin Berlin · DEGerman Centre for Cardiovascular Research · DENovartis (United States) · USUniversity of Glasgow · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsDiabetes is associated with a faster rate of renal function decline in patients with heart failure (HF). Sacubitril/valsartan attenuates the deterioration of renal function to a greater extent in patients with diabetes and HF with reduced ejection fraction compared with renin-angiotensin system inhibitors alone. We assessed whether the same may be true in HF with preserved ejection fraction (HFpEF). METHODS AND

resultsIn the PARAGON-HF trial in patients with HF and left ventricular ejection fraction of ≥45% (n = 4796), we characterized the effects of sacubitril/valsartan on changes in estimated glomerular filtration rate (eGFR) over a period of 192 weeks, and on the pre-specified renal composite outcome (eGFR reduction of ≥50%, end-stage renal disease, or death attributable to renal causes) in patients with (n = 2388) and without diabetes (n = 2408). The decline in eGFR was greater in patients with diabetes than in those without (-2.6 vs. -1.7 ml/min/1.73 m

conclusionSacubitril/valsartan, compared with valsartan, attenuates the decline of eGFR and reduces clinically relevant kidney events similarly among patients with HFpEF with and without diabetes.

Indexed as

Diabetes MellitusHeart FailureKidneyValsartanAminobutyratesAngiotensin Receptor AntagonistsBiphenyl CompoundsDrug CombinationsHumansStroke VolumeTetrazolesVentricular Function, LeftAminobutyratesAngiotensin Receptor AntagonistsBiphenyl CompoundsDrug CombinationssacubitrilTetrazolesValsartanDiabetesHeart failure with preserved ejection fractionRenal functionSacubitril/valsartan

Identifiers

PMID35119183
PMCPMC9305963
OpenAlexW4210280239

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.